Search Results - "Carleton, Mia"

Unmet Needs in the Evaluation, Treatment, and Recovery for 167 Children Affected by Acute Flaccid Myelitis Reported by Parents Through Social Media by Bove, Riley, Rowles, William, Carleton, Mia, Olivera, Erin, Sheehan, Mikell, Werdal, Heather P., Scott, Rachel, Axton, LaMay, Benson, Leslie

“…We aimed to characterize the outcomes of 167 children affected by acute flaccid myelitis by leveraging the power of social media. Members of a closed social…”
Get full text

160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee, Sworder, Brian, Hovanky, Vanna, Duran, George, Zhang, Tian, Khodadoust, Michael, Miklos, David, Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David

“…BackgroundMeasurable residual disease (MRD) is an important predictor of survival outcomes in both newly diagnosed and relapsed/refractory multiple myeloma…”
Get full text

Strengthening knowledge when data are scarce: the role of social media after AFM. (P5.6-066) by Bove, Riley, Carleton, Mia

“…Abstract only…”
Get full text

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas by Sworder, Brian J., Kurtz, David M., Alig, Stefan K., Frank, Matthew J., Shukla, Navika, Garofalo, Andrea, Macaulay, Charles W., Shahrokh Esfahani, Mohammad, Olsen, Mari N., Hamilton, James, Hosoya, Hitomi, Hamilton, Mark, Spiegel, Jay Y., Baird, John H., Sugio, Takeshi, Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, Sheybani, Natasha D., Schroers-Martin, Joseph G., Liu, Chih Long, Oak, Jean S., Jin, Michael C., Beygi, Sara, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Westin, Jason R., Khodadoust, Michael S., Natkunam, Yasodha, Majzner, Robbie G., Mackall, Crystal L., Diehn, Maximilian, Miklos, David B., Alizadeh, Ash A.

“…Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize…”
Get full text

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee L, Sworder, Brian, Hovanky, Vanna, Duran, George E, Zhang, Tian Y., Khodadoust, Michael S., Miklos, David B., Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David M.

Get full text

Experiences of sexual and gender minority people living with multiple sclerosis in Northern California: An exploratory study by Anderson, Annika, Dierkhising, Jason, Rush, Gillian, Carleton, Mia, Rosendale, Nicole, Bove, Riley

“…•Little research has been carried out at the intersection between sexual and gender minority identity and MS care.•Sexual health is under addressed in sexual…”
Get full text

Abstract PO2-13-10: Predicting outcomes in locally advanced breast cancer through profiling post-neoadjuvant tissue-based minimal residual disease by Ransohoff, Julia, Carleton, Mia, Birk, Alisha, Bean, Gregory, Telli, Melinda, Alizadeh, Ash, Ford, James, Duran, George, Khodadoust, Michael, Kurtz, David

“…Abstract Background: Neoadjuvant chemotherapy (NAC) for locally advanced breast cancer can down-stage disease prior to surgery, monitor chemo-sensitivity, and…”
Get full text

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas by Sworder, Brian, Kurtz, David M., Alig, Stefan K., Frank, Matthew J, Shukla, Navika D., Garofalo, Andrea, Macaulay, Charles, Shahrokh Esfahani, Mohammad, Olsen, Mari, Hamilton, James, Hosoya, Hitomi, Hamilton, Mark P, Spiegel, Jay Y., Baird, John H., Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, Sheybani, Natasha, Schroers-Martin, Joseph, Liu, Chih Long, Oak, Jean S, Jin, Michael C., Beygi, Sara, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Westin, Jason, Khodadoust, Michael S., Natkunam, Yasodha, Majzner, Robbie G., Mackall, Crystal L., Diehn, Maximilian, Miklos, David B., Alizadeh, Ash A.

Get full text

Abstract 5707: Tumor and immune determinants of response to anti-BCMA CAR T-cell therapy in multiple myeloma using cell-free DNA by Carleton, Mia, Hosoya, Hitomi, Tanaka, Kailee L., Sworder, Brian, Hovanky, Vanna, Sahaf, Bita, Frank, Matthew J., Duran, George E., Zhang, Tian Y., Arai, Sally, Iberri, David, Liedtke, Michaela, Miklos, David B., Khodadoust, Michael S., Sidana, Surbhi, Kurtz, David M.

“…Abstract Background: Multiple myeloma (MM) is an incurable disease with a heterogenous clinical course and genomic landscape. Autologous anti-BCMA chimeric…”
Get full text

Circulating Tumor DNA for Disease Characterization and Response Prediction in Myeloma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee, Sworder, Brian, Hovanky, Vanna, Duran, George E, Zhang, Tian Y, Khodadoust, Michael, Miklos, David B., Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David

Get full text

1 - Circulating Tumor DNA for Disease Characterization and Response Prediction in Myeloma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee, Sworder, Brian, Hovanky, Vanna, Duran, George E, Zhang, Tian Y, Khodadoust, Michael, Miklos, David B., Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David

Get full text

A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial by Bove, Riley, Anderson, Annika, Rowles, William, Rankin, Kelsey A., Hills, Nancy K., Carleton, Mia, Cooper, Joanna, Cree, Bruce A.C., Gelfand, Jeffrey M., Graves, Jennifer S., Henry, Roland G., Krysko, Kristen M, Rush, Gillian, Zamvil, Scott S., Joffe, Hadine, Chan, Jonah R., Green, Ari J.

“…•Alleviating vasomotor symptoms could improve QOL in menopausal women with MS.•This Phase Ib/IIa RCT evaluated: feasibility, tolerability, symptom response of…”
Get full text